ChemRxiv
These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
chrxiv-Chernyshev.pdf (1.2 MB)

Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs

preprint
submitted on 12.05.2020, 06:46 and posted on 14.05.2020, 12:01 by Anatoly Chernyshev
An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus. A docking study is conducted using a set of known drugs approved worldwide (ca. 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures. The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials.

History

Email Address of Submitting Author

a@xph.co.nz

Institution

XR Pharmaceuticals Ltd.

Country

New Zealand

ORCID For Submitting Author

0000-0002-1628-9318

Declaration of Conflict of Interest

I have no conflict of interests.

Licence

Exports

Logo branding

Licence

Exports